STOCKHOLM, April 6, 2021 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) today announces that the Annual Report
for 2020 now is available at the company's website:
www.medivir.com.
In the spring of 2020, Medivir was able to present promising
data from the phase Ia study and shortly thereafter initiate the
phase Ib study with MIV-818, our proprietary and wholly owned
candidate drug for liver cancer. In December, we succeeded in
renegotiating the old agreement with TetraLogic for birinapant,
which enabled us to sign a license agreement for birinapant with
IGM Biosciences in mid-January 2021.
In addition, at the beginning of 2021, we were able to carry out a
much-needed financing of the company with strong support from both
existing investors and new specialist investors. It is particularly
gratifying that the share issues provided Medivir an ownership base
with strong institutions in the lead.
This and much more can be found in Medivir's Annual Report 2020,
published today at www.medivir.com .
For additional information, please contact
Yilmaz Mahshid, CEO
Telephone: +46 8 5468 3100
E-mail: yilmaz.mahshid@medivir.com
Magnus Christensen, CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
MIV-818, a pro-drug designed to selectively treat liver cancer
cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Birinapant, a SMAC mimetic, is
exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be
developed in combination with IGM-antibodies for the treatment of
solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq
Stockholm's Small Cap list. www.medivir.com .
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/medivir-2020-annual-report-published,c3320252
The following files are available for download:
|
https://mb.cision.com/Main/652/3320252/1397591.pdf
|
Annual Report 2020
(PDF)
|
|
https://mb.cision.com/Public/652/3320252/9525b48fb42e114d.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/medivir-2020-annual-report-published-301263018.html
SOURCE Medivir
